XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Information
Note 17. Segment Information
We currently operate in one operating business segment focused on the global discovery, development and commercialization of proprietary therapeutics. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. We do not operate in any material separate lines of business or separate business entities with respect to our products or product development.
During the year ended December 31, 2023, total revenues generated by subsidiaries in the United States was approximately $3.5 billion and total revenues generated from subsidiaries in Europe and Japan was approximately $179.3 million. During the year ended December 31, 2022, total revenues generated by subsidiaries in the United States was approximately $3.2 billion and total revenues generated from subsidiaries in Europe was approximately $147.0 million. During the year ended December 31, 2021, total revenues generated by subsidiaries in the United States was approximately $2.9 billion and total revenues generated from subsidiaries in Europe was approximately $124.1 million.
As of December 31, 2023, property and equipment, net was approximately $432.3 million in the United States, approximately $314.4 million in Europe and approximately $4.8 million in Japan. As of December 31, 2022, property and equipment, net was approximately $442.0 million in the United States and approximately $295.8 million in Europe and approximately $1.5 million in Japan.